Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.49 USD | +0.47% | -11.10% | +131.97% |
13/05 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
08/05 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+131.97% | 61Cr | |
+29.03% | 4.82TCr | |
-0.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+11.48% | 2.56TCr | |
-22.74% | 1.9TCr | |
+9.06% | 1.29TCr | |
+30.01% | 1.2TCr | |
-1.51% | 1.18TCr |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Cantor Fitzgerald Starts Mind Medicine at Overweight With $3 Price Target